Kyverna Therapeutics KYTX
NASDAQ KYTX
$6.53 +0.01 (+0.15%)
As of: Oct 2, 2026 · 10:10 AM EDT

Kyverna Therapeutics (KYTX) Preferred Stock Liabilities (2023)

Updated

Kyverna Therapeutics (KYTX) recorded Preferred Stock Liabilities of $180.57 million in Q4 2023, unchanged from the prior quarter.

Analysis

Kyverna Therapeutics (KYTX) Preferred Stock Liabilities (2023) Analysis & Trends

Starting with Q1 2023, Kyverna Therapeutics' Preferred Stock Liabilities history includes 4 quarters.

  • Per Business Quant, the preceding three quarters came in at $180.57 million (Q3 2023), $145.73 million (Q2 2023) and $120.67 million (Q1 2023).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn -
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn -
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn -
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn -
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn -
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn -
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn -
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn -
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn -
10 Kyverna Therapeutics 418.68 Mn 418.68 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2023 180.57 Mn
Sep 30, 2023 180.57 Mn
Jun 30, 2023 145.73 Mn
Mar 31, 2023 120.67 Mn
API Access

Kyverna Therapeutics Preferred Stock Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=preferred-stock-liabilities&ticker=KYTX&period=max&api_key=YOUR_API_KEY